Resources
The National Pharmaceutical Council (NPC) is a health policy research organization dedicated to the advancement of good evidence and science, and to fostering an environment in the United States that supports medical innovation.
Filter by:
Topic
Topic
- Accountable Care Organizations
- Alternative Payment Models
- Biopharmaceutical Innovation
- Bundled Payments
- Clinical Pathways
- Decision Frameworks
- Elements of Value
- Evidence for Decision Making
- Formulary/Benefit Design
- Formulary Development
- Good Practices for Evidence
- Health Care Quality Measures
- Health Spending
- Health Spend Management
- High-Deductible Health Plans
- Impact on Outcome & Spending
- Individual Treatment Effects & Personalized Access
- Low-Value Care
- Pandemic Response
- Patient Cost Sharing
- Paying for Cures
- Policy & Regulatory Barriers
- Real-World Data
- Real-World Evidence
- Regulatory Barriers & Challenges
- Understanding Health Spending
- Utilization Management & Step Therapy
- Value-Based Contracts
- Value-Based Insurance Design
- Value Assessment
- Value Assessment Frameworks
- Value Assessment Methods
Resource Type
Audience
Audience
Display Only
Showing 587 Results
NPC in STAT: Paying for Curative Therapies: Our Challenges in Addressing Medicine’s Solutions
In a commentary published in STAT, National Pharmaceutical Council Executive Vice President and Chief Science Officer Robert Dubois, MD, PhD, outlines some creative thinking behind how we could…
NPC in Specialty Pharmacy Times: Going Below the Headlines on Health Spending in Four Steps
In his latest commentary for Specialty Pharmacy Times, NPC President Dan Leonard offers four suggestions to reconsider how we assess, analyze and apply the evidence and data around health spending to…
Controlling Health Care Costs Means Confronting Misconceptions
The only way that we can begin to reduce overspending on health care is if we base decisions on what the evidence indicates.
National Pharmaceutical Council and Anthem Support Health Affairs in Launching New Council on Health Care Spending and Value
NPC launched a broader stakeholder initiative funding research and supporting a series of papers and blog posts in Health Affairs last December. It is in service of this broader mission that NPC,…
Restrictions, Variations in Specialty Drug Coverage May Affect Physician and Patient Choices
According to a study from the Center for the Evaluation of Value and Risk in Health at Tufts Medical Center and NPC, coverage of specialty medicines by major U.S. commercial health plans varies…
NPC in Morning Consult: Does High Return Call for Greater Investment?
In his latest commentary for Morning Consult, NPC Chief Science Officer Robert W. Dubois explores new research that sheds light on which types of medical care have provided the greatest overall…
Are Payers Ready to Address the Financial Challenges Associated with Gene Therapy?
An article published on the Health Affairs Blog explores the tensions with paying for gene therapies via online market research with payers and highlights a few proposals to address these concerns.
Context Matters on Health Statistics
A single number doesn’t always tell the full story, and that’s the case when it comes to a recent report from AHIP asking how our health care premium dollars are being spent.
Survey Data Shows Physicians See Pharmaceuticals as Leading Contributor to Improved Health Outcomes
Research by RTI Health Solutions and the National Pharmaceutical Council shows the value of biopharmaceutical and pharmaceutical innovations to improving patient health.
FDA Clarifies What Information Can Be Exchanged With Health Decision-Makers
With the release of two guidance documents this week, the US Food and Drug Administration took significant steps to modernize how health care information is communicated. The final guidance released…
High Spending Growth Rates For Key Diseases Were Driven By Technology And Demographic Factors
Research published in the June 2018 edition of Health Affairs shows that increases in health care spending on key diseases can be attributed to several factors: the use of new and often…
NPC at ISPOR 2018: Gathering and Curating Real-World Data
The use and importance of real-world evidence (RWE) in clinical decision-making has been frequently cited by Food and Drug Administration (FDA) Commissioner Dr. Scott Gottlieb, so it’s not surprising…
NPC in in Specialty Pharmacy Times: Aiming for Value Over Volume in Cancer Drug Spending
In his latest column for Specialty Pharmacy Times, NPC President Dan Leonard takes a closer look at a presidential panel's report on "Promoting Value, Affordability, and Innovation in Cancer Drug…
Could expanding pre-deductible coverage help those with chronic conditions?
According to a new issue brief from VBID Health, providing pre-deductible coverage for medicines used to treat common chronic conditions could lower out-of-pocket costs and increase medication…